Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice. The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients who have a high suspicion for cardiac amyloidosis by AI algorithm

Locations
United States
California
Cedars-Sinai Medical Centre (Los Angeles)
RECRUITING
Los Angeles
Time Frame
Start Date: 2021-11-18
Estimated Completion Date: 2027-06-01
Participants
Target number of participants: 300
Treatments
Artificial Intelligence Screening for Cardiac Amyloidosis
An artificial intelligence algorithm will produce a probability of cardiac amyloidosis that will trigger referral to specialty clinic for further evaluation.
Sponsors
Leads: Cedars-Sinai Medical Center

This content was sourced from clinicaltrials.gov